Passionate about health and ethics issues, I had the chance with Pharmion and then Celgene to participate in the advent of immunotherapy by participating in the marketing in France of Imids from the beginning of the 2000s.
I wish to see the cure of an increasing number of cancers and I do this by promoting the Good Use of drugs with as much scientific rationale as possible, thus guaranteeing the best benefit/risk ratio for patients.
In charge of the Erwinase drug, a new Asparaginase coming from erwinia in Lymphoblastic Acute Leukemia.
Area : Secteur : Moitié Est de la France : Lille, Paris, Reims, Strasbourg, Nancy, Dijon, Besançon, Lyon, Saint-Etienne, Clermont-Ferrant, Grenoble, Marseille et Nice
Same missions as at Celgene. Sharing Celgene and BMS cultures. We have been pursuing the same objective for a long time: to understand Cancer and to fight against this disease for the good of patients, families and society.
2019/2021 Development of Imnovid (pomalidomide)
Result : 1st in France in terms of implementation and growth in 2021 on the Imnovid molecule, still in the top 3 in France since I have been in charge of this drug.
Leaving the company on December 21, 2021 - I realized that I was not cut out to work in large top-down structures. I am a deeply autonomous person who likes prospecting in large sectors and working upstream of the launches of innovative drugs with high added value in rare diseases. I stayed 17 years in this company, it was time for me to change.
Management of 3 molecules. Management of proper use, drug safety, training. Creation of projects in Burgundy, Franche-Comté & Champagne. (Azacitidine (SMD and LAM), Lenalidomide (SMD Del5q, MCL), Pomalidomide (multiple myeloma), focus on Pomalidomide in relapsed Myeloma.
Hospital Scientific Associate in myelodysplastic syndromes (MDS). Medical information and information on 5-azacitidine in myelodysplastic syndromes. Public relations. Project Manager. Visit of professors and doctors in onco-hematology and oncology.
Creation of the Celgene Oncology Business Unit in France. My assignment was to monitor and report on the safe use of Abraxane (Paclitaxel), indicated for the first-line treatment of pancreatic adenocarcinoma in Burgundy, Champagne and Franche-Comté. Education, public relations and medical information on 5-azacitidine in myelodysplastic syndromes for professors and physicians in onco-hematology as well as opinion leaders in MDS.
Education, public relations and medical information on 5-azacitidine in myelodysplastic syndromes for professors and physicians in onco-hematology as well as opinion leaders in MDS.
**Results: **In the top 5 sectors, all products combined. Implementation of innovative and differentiating projects.
Pre-marketing of Thalidomide (IFM 99/06) in myelomas and 5-azacitidine (GFM AZA001) in myelodysplastic syndromes. 1/4th of France Territory East and South East.
Preparation of marketing authorizations and the launch of Thalidomide and Vidaza.
Hemostasis and coagulation: Responsible for the development of Refludan (Lepirudin) Anti-IIa Anti-Xa in HIT.
Hospital and Pharmacy product specialist in oral and enteral nutrition in Dijon, Burgundy, France.
Launch of the Clinutren brand in France.
Results : Top 1 Champion of Sales two years after joining the company. I helped Nestlé Homecare to launch in France by introducing the company Référence Santé, its distribution network in France, thus enabling Nestlé Homecare to be ready to start its activities on time.
